ViewRay Inc.
ViewRay Reports New Outcomes Data Demonstrating Prolonged Survival for Inoperable Pancreatic Cancer Patients Presented at Leading Radiation Oncology Meeting
Findings showed longer median survival of 26 months compared to 12-15 months typically seen in patients receiving chemotherapy and standard radiation therapy. The 2-year overall survival was over 50 percent, which is more than double the expected 2-year rate of 20 percent with lower dose radiation.
